Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Orexo AB ( (SE:ORX) ) has provided an announcement.
Orexo has completed its transaction with Dexcel Pharma USA, acquiring the full US rights to Zubsolv, its buprenorphine/naloxone sublingual tablet for opioid use disorder, for an upfront cash consideration of USD 91 million plus USD 3.8 million in inventory value and potential contingent payments of up to USD 16.8 million tied to net sales in 2026–2027. The company plans to use the proceeds to redeem its outstanding corporate bond and to sharpen strategic focus on its AmorphOX-based pipeline, including overdose and anaphylaxis rescue drugs such as Izipry, OX640 and OX390, while adopting a partnering-led development model that aims to reduce risk, support investment in biologics applications like GLP‑1 agonists and vaccines, and leverage its US legacy and BARDA collaboration for future commercialization.
The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.
More about Orexo AB
Orexo AB is a Swedish biotechnology company focused on treatments for severe diseases and life‑saving rescue medications, built around its proprietary AmorphOX drug delivery technology, which enhances bioavailability and stability for small and large molecules. With more than 30 years of experience and several approved products worldwide, Orexo is advancing a diversified clinical and pre‑clinical pipeline, often in collaboration with partners, and is listed on Nasdaq Stockholm with ADRs trading on the OTCQX market in the US.
Average Trading Volume: 111,354
Technical Sentiment Signal: Buy
Current Market Cap: SEK960.3M
See more data about ORX stock on TipRanks’ Stock Analysis page.